Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.

ABSTRACT: Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the current guidelines are derived from small non-randomized studies, case series, or simply from the consensus of experts. Guideline-directed therapy of HCM includes non-selective drugs such as disopyramide, non-dihydropyridine calcium channel blockers, or β-adrenergic receptor blockers, mainly used in patients with symptomatic obstruction of the outflow tract. Following promising preclinical studies, several drugs acting on potential HCM-specific targets were tested in patients. Despite the huge effor

SUBMITTER: Palandri C 

PROVIDER: S-EPMC9209358 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature